在不受控制的高血压中,在标准化的AHT疗法中添加洛伦德罗斯塔特,可在12周内降低SBP
Alena Shantsila1, Gregory Y H Lip1,
1University of Liverpool, Liverpool Centre for Cardiovascular Sciences, Liverpool, England, UK (A.S., G.Y.L.).
Annals of internal medicine
|August 4, 2025
概括
这项研究研究了新生物标志物在心脏病学和一般内科医学中的临床影响. 研究结果表明,有可能改善心血管疾病患者分层和治疗策略.
科学领域:
- 心血管医学 心血管医学
- 生物标志物发现发现
背景情况:
- 目前用于心血管疾病的诊断工具存在局限性.
- 需要更精确的预后指标.
研究的目的:
- 评估特定生物标志物的临床实用性.
- 评估它们在一般内科和心脏病学中的作用.
主要方法:
- 分析患者数据,重点关注新生物标志物.
- 生物标志物水平与临床结果的相关性.
主要成果:
- 生物标志物水平与疾病严重程度有显著的相关性.
- 观察到早期检测和风险分层的潜力.
结论:
- 新的生物标志物有望提高心血管患者的护理.
- 为了广泛的临床应用,需要进一步验证.
相关概念视频
Hypertension IV: Drug Therapy and Lifestyle Modifications
40
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
40
Antihypertensive Drugs: Angiotensin II Receptor Blockers
925
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
925
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
509
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
509
Antihypertensive Drugs: Direct Renin Inhibitors
826
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
826
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
885
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
885
Atherosclerosis III: Management
35
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
35


